Nanoform has appointed Mads Laustsen as a non-executive board member. This appointment will further strengthen the experienced Nanoform board and support the company as it increases its ability to deliver nanonized APIs for global partners across the pipeline from late stage drug discovery to commercial.
Nanoform has appointed Mike Rea as its Strategic Innovation Advisor. The role will involve working closely with Nanoform to maximise the value its proprietary nanonization technology can deliver to pharmaceutical partners and patients globally.
Nanoform has appointed Henri von Haartman as Director of Investor Relations. The newly created role will enrich investor relations as Nanoform seeks to further its shareholder base and continue its international growth, including expansion into the US market.
Nanoform announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.
Nanoform has unveiled a new brand identity and website. The evolution of Nanoform’s brand reflects how the company is using innovation to transform the pharmaceutical industry and support its global partners as they develop life-changing medicines.
Our CCO, Christian Jones, recently discussed the advantages of our nanonization services with Mike Ward at EBD Group’s BIO-Europe Spring 2019. Watch the Scrip video to learn more:
Nanoform accelerates growth with Director of Project Management appointment Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, will appoint Miguel Cansado as its Director of Project Management.
Nanoform awarded with a Seal of Excellence from the European Commission Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has received a Seal of Excellence from the European Commission for its “Nanomedicines of Tomorrow” project.